C oncurrent use of prescription opioids and benzodiazepines is associated with increased risk for overdose and death. In a study from the U.S. Department of Veterans Affairs (VA), veterans concurrently prescribed both types of medication had more than twice the risk for overdose death, and this risk increased among patients prescribed higher benzodiazepine doses (1) . Other studies of nonveterans have corroborated an association between concomitant use of opioids and benzodiazepines and overdose death (2) (3) (4) (5) (6) (7) . In addition, nonbenzodiazepine hypnotics (such as zolpidem, eszopiclone, and zaleplon) may increase risk for opioid overdose, particularly among persons with anxiety or posttraumatic stress disorder (6, 8 -10) .
Against the backdrop of rapidly increasing rates of death due to opioid overdose (6, 11, 12) , this growing body of evidence led several organizations to formalize recommendations against widespread concurrent use of opioids and benzodiazepines. Such use is now cautioned against by opioid product labeling (13) , VA guidelines (14), and opioid prescribing guidelines from the Centers for Disease Control and Prevention (CDC) (12) . The CDC guidelines also recommend that opioid dosages not exceed 90 morphine milligram equivalents (MME) per day and that use of opioids with other sedating medications be assessed carefully for risks and benefits (12) . Opioid and benzodiazepine overlap is now measured by the Pharmacy Quality Alliance (PQA) (15). This PQA measure of opioid-benzodiazepine overlap is being tracked by the Centers for Medicare & Medicaid Services (CMS) as of 1 January 2018 (16).
Among veterans cared for in the VA health care system, clinical assessment of concurrent opioid and benzodiazepine use can be complicated by coprescribing from outside the VA, because most veterans are enrolled in other forms of health insurance. For example, more than 30% of veterans enrolled in VA health care are also enrolled in Medicare Part D (17) . Use of 2 or more health care systems ("dual-system use") can result in poorly coordinated care that increases the risk for prescribing errors. Dual-system use has been associated with potentially unsafe medication prescribing among patients with dementia (18) , unnecessary use of health care resources (19, 20) , increased unsafe opioid prescribing (21) (22) (23) , and increased risk for rehospitalization after stroke (24) , among other adverse outcomes (25) (26) (27) (28) . Although use of prescription drug monitoring programs (PDMPs) is routinely recommended to assess opioid prescribing across payers (12) , less attention has been paid to benzodiazepine prescriptions, alone or in combination with other medications. For example, most states have no current or planned requirement that prescribers check a PDMP when they prescribe a benzodiazepine, and local rules about monitoring opioid prescriptions have historically varied widely by state (29) .
The purpose of this study was to assess the association between receiving medications from both VA and Medicare Part D (dual use) and receipt of overlapping opioid and benzodiazepine prescriptions. We hypothesized that dual use would increase the risk for such potentially unsafe prescribing.
METHODS

Data Sources
We linked comparable data from VA and CMS at the patient level. We obtained relevant VA data from the VA Pharmacy Benefits Management Services, which retain information on all prescriptions dispensed to VA patients, and the VA Corporate Data Warehouse, which contains information on patient demographics, encounters (including inpatient, outpatient, and skillednursing care), and diagnosis codes. We obtained CMS data on inpatient and skilled-nursing facility stays from the Medicare Provider Analysis and Review file; enrollment and sociodemographic data from the CMS Beneficiary Summary File; diagnoses from the Medicare Provider Analysis and Review file and home health, hospice, outpatient, and carrier files; and dispensed prescriptions from the Medicare Part D files on prescription drug events.
Study Sample and Definition of Dual Use
We identified all patients enrolled in both VA and Medicare Part D in calendar year 2013 who filled at least 1 opioid prescription from either source, including Medicare fee-for-service and managed care enrollees (n = 654 578). Appendix Table 1 (available at Annals.org) lists opioids used in the analyses, which did not include sublingual buprenorphine formulations. We excluded 13 454 patients (2.1%) for whom MME dosage could not be calculated for 1 or more of the opioids received (for example, for certain oral liquid dosage forms). We also excluded an additional 29 410 patients (4.5%) who received hospice or palliative care services (15). The primary outcome measure (described in the next section) was constructed using the PQA definition of opioid-benzodiazepine overlap; to be eligible for PQA overlap, patients must have at least 2 opioid prescriptions filled on at least 2 separate days with a total of at least 15 days' supply in a year (15). Thus, we excluded patients who had only 1 opioid prescription filled (199 129 [30.4%]), did not reach a total of 15 days' supply (43 694 [6.7%]), or both. Cohort construction is detailed in Figure 1 .
The final cohort was categorized by the source of each patient's prescription medications in 2013 (including all medications, not only opioids or benzodiazepines), which we refer to as "dual-use status." Patients who received all of their medications from VA sources were considered "VA-only users," those who received all of their medications from Medicare Part D were considered "Medicare-only users," and those who received Dual-use categories were defined on the basis of receipt of all medications, not only opioids or benzodiazepines. MME = morphine milligram equivalents; VA = U.S. Department of Veterans Affairs.
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Study Outcomes
We combined Medicare Part D data and dispensing data from VA Pharmacy Benefits Management Services to identify all opioids and benzodiazepines dispensed to patients retained in the cohort in 2013. As in prior analyses (21, 30) , MME was calculated for all opioids using conversions from the CDC. We assumed that every prescription was dispensed on the date of dispensing and covered a number of days equal to its days' supply. Exposures to opioids, benzodiazepines, and sedatives were coded for each day in 2013.
We examined 2 primary outcomes. The first was the percentage of patients meeting the PQA definition of opioid-benzodiazepine overlap: receipt of 2 or more prescriptions for benzodiazepines filled on 2 or more days with at least 30 days of overlap with opioid prescriptions (15). The second outcome was the percentage of patients with overlapping use of high-dose opioids (>120 MME) and benzodiazepines for at least 30 days, without restriction on the number of benzodiazepine prescriptions. The 120-MME threshold is used by PQA in its operationalization of high-dose opioid use and has been adopted in an assessment of provider quality by the National Committee for Quality Assurance (15, 31). We wanted to identify not only concurrent opioid-benzodiazepine use but also concurrent use of a high-dosage opioid, because this confers increased risk for overdose and death (12) . In a sensitivity analysis, we also defined high-dose opioid-benzodiazepine overlap using the CDC threshold of greater than 90 MME (12) as the cut point instead of greater than 120 MME.
In secondary analyses, we combined benzodiazepines and the sleep aids eszopiclone, zaleplon, and zolpidem into a group operationally defined as sedatives. We then examined the number and percentage of patients who were exposed to an opioid and an overlapping sedative for at least 30 days or were exposed to a daily opioid dose greater than 120 MME with an overlapping sedative for at least 30 days.
Primary Variables and Covariates
The primary independent variable of interest was each patient's medication dual-use status (VA-only, Medicare-only, or dual use) in 2013. Covariates were identified in a manner consistent with previous work on dual enrollment and high-dose opioid prescribing and chosen on the basis of factors believed to affect either dual-use status or use of opioids and benzodiazepines (21) . Demographic variables included age, sex, and race/ethnicity. Race/ethnicity was primarily assessed using VA data; if VA data were missing, the Medicare race/ethnicity variable was used instead (32) . We incorporated markers of socioeconomic status or need for health care services, including disability insurance benefits as the reason for initial Medicare enrollment and enrollment in Medicaid or low-income subsidies. We also included an indicator of HMO enrollment status in 2013. Geographic data were encoded by capturing the ZIP code of patient residence in 2013 from Medicare. This ZIP code was then used with the 2013 Area Health Resources File to obtain an Urban Influence Code, a measure of rurality used by the U.S. Department of Agriculture's Economic Research Service (33) . We also used ZIP codes to approximate driving distance to the nearest VA primary care clinic and to determine U.S. census region (South; West; Northeast; Midwest; or outside the 50 states and Washington, DC).
We considered the number of distinct drugs prescribed, excluding benzodiazepines and opioids, to adjust for comorbid conditions (34) in a manner consistent with previous analyses (35) . We also captured In a sensitivity analysis, we repeated all analyses on the subgroup of fee-for-service Medicare beneficiaries (for whom diagnosis data were available) and adjusted for risk using ICD-9 -based indicators of health status, including the number of Elixhauser comorbid conditions (36) in the prior year, pain or cancer diagnoses, and substance use disorder.
Statistical Analysis
We summarized and compared patient characteristics across the 3 prescription source groups using 2 tests for categorical variables and analysis-of-variance tests or Kruskal-Wallis tests for continuous variables. We also calculated and compared the percentage of patients with each outcome using 2 tests. To examine associations between the extent of fragmentation in medication supply and opioid-benzodiazepine overlap, we plotted the relationship between the proportion of prescriptions (measured by total days' supply) provided by VA (as opposed to Medicare Part D) against the percentage of patients with the 2 outcomes (PQA overlap and high-dose opioid-benzodiazepine overlap).
To account for potential selection bias based on differences in observable characteristics across prescription source groups, we used augmented inverse probability weighting to assess the adjusted association between prescription source group and opioidbenzodiazepine overlap. Augmented inverse probability weighting is a doubly robust method that combines regression adjustment and inverse probability-weighted methods. First, inverse probability of treatment weights were developed using multinomial logistic regression to estimate the probability of belonging to each dualuse status group; then, weighted multivariable logistic regression was used to model the outcomes across prescription source groups using the aforementioned covariates (37) . We assessed the balance of covariates between groups using standardized differences, where a value less than 0.1 is considered negligible (38) . We used Stata procedure teffects (treatment effects estimation for observational study) with the logit link function to estimate the adjusted probabilities for direct comparison of dual-use status groups and then used non- 
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linear combination (nlcom) to estimate the adjusted risk ratios (aRRs). We retained presence of nonbenzodiazepine sedatives (eszopiclone, zaleplon, and zolpidem) as a covariate when adjusting for benzodiazepine overlap, but not when adjusting for overall sedative overlap. Differences in percentages, risk ratios, and 95% CIs were calculated. Because only 0.3% of data were missing across all variables, we used complete-case analysis by removing those records in multivariable models. We did 2 sensitivity analyses to assess the robustness of our estimates. First, we redefined high-dose opioid-benzodiazepine overlap using a cut point of greater than 90 MME-a value consistent with CDC guidelines (12)-instead of greater than 120 MME. Second, we repeated all analyses on the subgroup of feefor-service Medicare beneficiaries, for whom ICD-9 -based indicators of health status are available. We adjusted for the number of Elixhauser comorbid conditions (36) and presence of substance use disorder diagnoses in the prior year (2012) and for ICD-9 -based indicators of pain or cancer diagnoses throughout 2013.
Analyses were done using SAS, version 9.4 (SAS Institute), and StataMP, version 15. Approval was obtained from the Institutional Review Board at the VA Pittsburgh Healthcare System.
Role of the Funding Source
The funders had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation of the manuscript.
RESULTS
The final cohort comprised 368 891 patients enrolled in both VA and Medicare Part D who received at least 2 opioid prescriptions on at least 2 separate days with more than 15 days of total exposure in 2013. The mean age of the entire cohort was 70.2 years, and approximately 72% of participants were aged 65 years or older. Most of the cohort was male (96.1%) and nonHispanic white (79.2%) ( Table 1 ). In the final cohort, 67 472 persons (18.3%) received prescriptions only from the VA ("VA-only" group), 111 641 (30.3%) received prescriptions only from Medicare Part D ("Medicare-only" group), and 189 778 (51.4%) received 1 or more prescriptions from each source ("dual-use" group).
Compared with veterans receiving medication from the VA only, dual users were slightly older, were more likely to be white, were prescribed a larger number of unique medications, were less likely to be eligible for both Medicaid and low-income subsidies, and were less likely to have a disability as the original reason for Medicare enrollment ( Table 1) . Appendix Table 3 (available at Annals.org) provides additional information about comorbid conditions among the subgroup of Medicare fee-for-service enrollees.
Unadjusted Overlap by Dual-Use Status
Overall, 27.8% of veterans had at least 1 day of opioid-benzodiazepine overlap, and the average overlap among all veterans analyzed was 36.4 days. The dual-use group had the highest proportion with any overlap (31.4%) and the greatest number of days of overlap (mean, 43.2 days) (P < 0.001). We observed a similar pattern when measuring days of overlap between opioids and all sedatives ( Table 2) .
Opioid-benzodiazepine overlap as defined by PQA occurred in 17.3% of VA-only users, 16.5% of Medicare-only users, and 23.1% of dual users (P < 0.001) ( Table 2) . High-dose opioid-benzodiazepine overlapped for at least 30 days in 2.3% of VA-only users, 2.9% of Medicare-only users, and 4.7% of dual users (P < 0.001). We saw similar patterns across prescription source groups when examining opioid overlap with sedatives, and the dual-use group had higher rates of at least 30 days of opioid-sedative overlap and at least 30 days of high-dose opioid-sedative overlap ( Table 2) . Figure 2 details the relationship between the proportion of all prescriptions provided by the VA and the percentage of patients with either PQA overlap or highdose opioid-benzodiazepine overlap. The relationships followed a dose-response pattern: Rates of overlap were higher when prescriptions were more evenly split between the VA and Medicare Part D and lower when prescriptions were received primarily from 1 system. 
Extent of Dual Use and Degree of Overlap
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Overlap was most prevalent in patients with approximately 60% VA use and 40% Medicare use; 26.7% of this group had PQA overlap, and 6.6% had highdose opioid-benzodiazepine overlap ( Figure 2 ).
Adjusted Analyses of Overlap by Dual-Use Status
After adjustment, all standardized differences across dual-use groups in the propensity score-weighted model were less than 0.1 (Appendix Table 4 , available at Annals.org). Dual users were more likely to have PQA opioid-benzodiazepine overlap than VA-only users (aRR, 1.27 [95% CI, 1.24 to 1.30]) and Medicare-only users (aRR, 1.12 [CI, 1.10 to 1.14]) ( Table 3) . Dual users were also more likely to have high-dose opioid-benzodiazepine overlap than VA-only users (aRR, 2.23 [CI, 2.10 to 2.36]) and Medicare-only users (aRR, 1.06 [CI, 1.02 to 1.11]). We found similar adjusted associations when examining overlapping opioids and sedatives (Appendix Table 5 , available at Annals.org) and when the cutoff for high-dose opioids was set to greater than 90 MME (Appendix Table 6 , available at Annals.org).
The sensitivity analysis of fee-for-service Medicare enrollees (n = 198 276), with additional adjustment for comorbid conditions using ICD-9 codes, produced similar results (Appendix Table 7 , available at Annals .org). Dual use was associated with higher risk for PQA opioid-benzodiazepine overlap than VA-only use (aRR, Table 7 ).
DISCUSSION
In a national cohort of veterans dually enrolled in VA and Medicare Part D who received an opioid from at least 1 of these systems, receiving prescription medications from both was associated with a 27% increased risk for overlapping opioids and benzodiazepines and more than twice the risk for overlapping high-dose opioids and benzodiazepines, compared with receiving prescriptions from the VA alone. Receipt of prescriptions from both VA and Medicare was also associated with greater risk for opioid-benzodiazepine overlap compared with Medicare alone, although the magnitude of the difference was smaller. As the VA and Medicare work to mitigate the risks of prescription opioids, these findings suggest that receipt of medications from more than 1 health care system is a key risk factor for unsafe prescribing practices.
These results are compatible with the findings of other recent observational studies that identify the risks associated with concomitant VA and non-VA care. Dual prescribing of medications has been associated with greater risk for receiving potentially unsafe medications in elderly persons with dementia (18) and greater risk for receiving high-dose prescription opioids for a long duration (21) . Another study done in a single statewide PDMP found 3-fold higher odds of overlapping opioidbenzodiazepine use among veterans with 2 prescription sources (23) . In contrast to our analyses, this study used only 1 day of concomitant prescriptions to define overlap and adjusted for only sex and age. Our additional finding of a dose-response relation between the proportion of prescriptions provided by VA and Medicare and 2 robust measures of opioid-benzodiazepine overlap extends the prior work and supports the contention that care fragmentation among dual users contributes to potentially unsafe prescribing practices.
It is particularly troubling that rates of overlapping opioids and benzodiazepines in which the opioid dosage was very high (>120 MME/d) were twice as common among dual users as among VA-only users. High opioid dosages alone are a risk factor for adverse events, including overdose, and are a major focus of quality improvement efforts around opioids and the CDC opioid prescribing guidelines (12) . Opioid-benzodiazepine coprescribing is similarly a target of CDC and VA guidelines (12, 14) . However, the combination of high opioid dosage and overlap with benzodiazepines has not been explicitly addressed in these guidelines, even though the risks of combining these medications are magnified at high dosages (3) . Despite the low rates of high-dose opioid-benzodiazepine overlap in our sample, the substantially increased risk among dual users requires attention.
Although the VA electronic health record system can make prescribers aware of diagnoses and treatments from other VA facilities, it does not routinely capture and report non-VA system use. The VA's Opioid Safety Initiative and other opioid safety programs now track dispensing of opioids and benzodiazepines, but they use VA data only (39) . Prescription drug monitoring databases across the nation provide an additional measure of decision support. However, the onus still falls on providers to manually check these databases, which are not yet incorporated into VA electronic health records. Such integration could build on an automated notification system that was correlated with a reduction in concomitant prescribing of opioids and benzodiazepines in a VA quality improvement project (40) . Although many physicians are now required to check PDMPs before issuing opioid prescriptions, this is not the case for benzodiazepine prescriptions; this is especially problematic when patients receive prescriptions through unconnected health care systems or payers, as in dual use of VA and non-VA benefits.
This study has important limitations. First, our data do not capture medications purchased without insurance or illicitly and consequently may underestimate the actual frequency of opioid-benzodiazepine overlap. Second, temporal trends (such as the VA's Opioid Safety Initiative or recent improvements in submission of VA prescription data to state PDMPs) (39) may have affected concomitant opioid-benzodiazepine use since the time frame of our study. Nonetheless, to our knowledge these data represent the first national assessment of opioid-benzodiazepine overlap across health systems Overlapping Opioid and Benzodiazepine Prescriptions Among Veterans ORIGINAL RESEARCH within either the VA or Medicare. Third, despite the robust statistical methods applied, the potential for unmeasured confounding remains in this cross-sectional study. Regardless of the causal relationship, however, our findings clearly document that dual medication prescribing is a key marker of greater risk for opioid-benzodiazepine overlap. Fourth, the study was restricted to patients who were eligible to meet the PQA definition of opioid-benzodiazepine overlap (that is, ≥2 opioid prescriptions and a total of ≥15 days of exposure in 2013) and to veterans enrolled in Medicare Part D, which limits the generalizability of our study findings. Finally, our analysis focused on process measures of prescribing safety and did not capture medical outcomes, such as overdose or death.
In conclusion, among a national cohort of veterans dually enrolled in the VA and Medicare Part D, receiving prescription medications from both sources was associated with greater risk for receiving potentially unsafe overlapping opioids and benzodiazepines compared with receiving prescriptions from either source alone. These findings highlight the need to enhance coordination of care across health care systems to optimize the quality and safety of prescribing. 
